160 related articles for article (PubMed ID: 35880680)
1. Increased Expression of Interleukin-13 Receptor in Ileum Associated With Nonresponse to Adalimumab in Ileal Crohn's Disease.
Wong ECL; Yusuf A; Pokryszka J; Dulai PS; Colombel JF; Marshall JK; Reinisch W; Narula N
Inflamm Bowel Dis; 2023 Jun; 29(6):875-882. PubMed ID: 35880680
[TBL] [Abstract][Full Text] [Related]
2. Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn's Disease: Results from the EXTEND Trial.
Reinisch W; Colombel JF; D'Haens G; Sandborn WJ; Rutgeerts P; Geboes K; Petersson J; Eichner S; Zhou Q; Robinson AM; Read HA; Thakkar R
J Crohns Colitis; 2017 Apr; 11(4):425-434. PubMed ID: 27815351
[TBL] [Abstract][Full Text] [Related]
3. Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease.
Danese S; Sandborn WJ; Colombel JF; Vermeire S; Glover SC; Rimola J; Siegelman J; Jones S; Bornstein JD; Feagan BG
Gastroenterology; 2019 Oct; 157(4):1007-1018.e7. PubMed ID: 31279871
[TBL] [Abstract][Full Text] [Related]
4. Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease.
Narula N; Wong ECL; Dulai PS; Marshall JK; Jairath V; Reinisch W
Am J Gastroenterol; 2022 Jul; 117(7):1106-1117. PubMed ID: 35435862
[TBL] [Abstract][Full Text] [Related]
5. Ulcer Size After Induction Therapy Performs Better Than Symptom Assessment for Prediction of One Year Endoscopic Remission in Crohn's Disease: A Post Hoc Analysis.
Pray C; Wong ECL; Aruljothy A; Dulai PS; Marshall JK; Reinisch W; Narula N
Inflamm Bowel Dis; 2023 Aug; 29(8):1263-1271. PubMed ID: 36179118
[TBL] [Abstract][Full Text] [Related]
6. Endoscopic response to tumor necrosis factor inhibitors predicts long term benefits in Crohn's disease.
Alfaro I; Masamunt MC; Planell N; López-García A; Castro J; Gallego M; Barastegui R; Giner A; Vara A; Salas A; Ricart E; Panés J; Ordás I
World J Gastroenterol; 2019 Apr; 25(14):1764-1774. PubMed ID: 31011260
[TBL] [Abstract][Full Text] [Related]
7. Ileal and Rectal Ulcer Size Affects the Ability to Achieve Endoscopic Remission: A Post hoc Analysis of the SONIC Trial.
Narula N; Wong ECL; Aruljothy A; Dulai PS; Colombel JF; Marshall JK; Ferrante M; Reinisch W
Am J Gastroenterol; 2020 Aug; 115(8):1236-1245. PubMed ID: 32759621
[TBL] [Abstract][Full Text] [Related]
8. Ileal or Colonic Histologic Activity Is Not Associated With Clinical Relapse in Patients With Crohn's Disease in Endoscopic Remission.
Hu AB; Tan W; Deshpande V; Ananthakrishnan AN
Clin Gastroenterol Hepatol; 2021 Jun; 19(6):1226-1233.e1. PubMed ID: 32360823
[TBL] [Abstract][Full Text] [Related]
9. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease.
Geboes K; Rutgeerts P; Opdenakker G; Olson A; Patel K; Wagner CL; Marano CW
Curr Med Res Opin; 2005 Nov; 21(11):1741-54. PubMed ID: 16307694
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab for maintenance of remission in Crohn's disease.
Townsend CM; Nguyen TM; Cepek J; Abbass M; Parker CE; MacDonald JK; Khanna R; Jairath V; Feagan BG
Cochrane Database Syst Rev; 2020 May; 5(5):CD012877. PubMed ID: 32413933
[TBL] [Abstract][Full Text] [Related]
11. Adalimumab for induction of remission in Crohn's disease.
Abbass M; Cepek J; Parker CE; Nguyen TM; MacDonald JK; Feagan BG; Khanna R; Jairath V
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31742665
[TBL] [Abstract][Full Text] [Related]
12. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
Colombel JF; Panaccione R; Bossuyt P; Lukas M; Baert F; Vaňásek T; Danalioglu A; Novacek G; Armuzzi A; Hébuterne X; Travis S; Danese S; Reinisch W; Sandborn WJ; Rutgeerts P; Hommes D; Schreiber S; Neimark E; Huang B; Zhou Q; Mendez P; Petersson J; Wallace K; Robinson AM; Thakkar RB; D'Haens G
Lancet; 2017 Dec; 390(10114):2779-2789. PubMed ID: 29096949
[TBL] [Abstract][Full Text] [Related]
13. Mucosal healing of ileal lesions is associated with long-term clinical remission after infliximab maintenance treatment in patients with Crohn's disease.
Beppu T; Ono Y; Matsui T; Hirai F; Yano Y; Takatsu N; Ninomiya K; Tsurumi K; Sato Y; Takahashi H; Ookado Y; Koga A; Kinjo K; Nagahama T; Hisabe T; Takaki Y; Yao K
Dig Endosc; 2015 Jan; 27(1):73-81. PubMed ID: 24833527
[TBL] [Abstract][Full Text] [Related]
14. Histologic Healing Is More Strongly Associated with Clinical Outcomes in Ileal Crohn's Disease than Endoscopic Healing.
Christensen B; Erlich J; Gibson PR; Turner JR; Hart J; Rubin DT
Clin Gastroenterol Hepatol; 2020 Oct; 18(11):2518-2525.e1. PubMed ID: 31812654
[TBL] [Abstract][Full Text] [Related]
15. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ;
Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
[TBL] [Abstract][Full Text] [Related]
16. Reduced numbers of mucosal DR(int) macrophages and increased numbers of CD103(+) dendritic cells during anti-TNF-α treatment in patients with Crohn's disease.
Dige A; Magnusson MK; Öhman L; Hvas CL; Kelsen J; Wick MJ; Agnholt J
Scand J Gastroenterol; 2016; 51(6):692-9. PubMed ID: 26784676
[TBL] [Abstract][Full Text] [Related]
17. Correlation and concordance measures between clinical, endoscopic and histological scores activity in Crohn's disease under treatment.
Tajra JB; Calegaro JU; de Paula AP; Bachour D; Silveira D; Lozi M; Cavalcanti H
Scand J Gastroenterol; 2019 Apr; 54(4):441-445. PubMed ID: 30939952
[No Abstract] [Full Text] [Related]
18. Clinical and Pharmacokinetic Factors Associated With Adalimumab-Induced Mucosal Healing in Patients With Crohn's Disease.
Watanabe K; Matsumoto T; Hisamatsu T; Nakase H; Motoya S; Yoshimura N; Ishida T; Kato S; Nakagawa T; Esaki M; Nagahori M; Matsui T; Naito Y; Kanai T; Suzuki Y; Nojima M; Watanabe M; Hibi T;
Clin Gastroenterol Hepatol; 2018 Apr; 16(4):542-549.e1. PubMed ID: 29104132
[TBL] [Abstract][Full Text] [Related]
19. Higher Adalimumab Levels Are Associated with Histologic and Endoscopic Remission in Patients with Crohn's Disease and Ulcerative Colitis.
Yarur AJ; Jain A; Hauenstein SI; Quintero MA; Barkin JS; Deshpande AR; Sussman DA; Singh S; Abreu MT
Inflamm Bowel Dis; 2016 Feb; 22(2):409-15. PubMed ID: 26752470
[TBL] [Abstract][Full Text] [Related]
20. Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's disease: correlation with SES-CD and clinical-biological markers.
Stoppino LP; Della Valle N; Rizzi S; Cleopazzo E; Centola A; Iamele D; Bristogiannis C; Stoppino G; Vinci R; Macarini L
BMC Med Imaging; 2016 May; 16(1):37. PubMed ID: 27149857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
